Table 4

Regression and progression of histopathology by different treatment arms^*

Group	No change	Regression			Progression
Group	n	n	OR (95% CI)^*	p Value	n	OR (95% CI)^*	p Value
Intention-to-treat analysis
Placebo	78	99	1.00		57	1.00
Anti-Hp+celecoxib	59	114	1.50 (0.97 to 2.32)	0.067	47	1.06 (0.63 to 1.78)	0.833
Anti-Hp+placebo	55	126	1.80 (1.16 to 22.78)	0.009	52	1.24 (0.74 to 2.09)	0.411
Celecoxib+placebo	61	120	1.55 (1.01 to 22.38)	0.046	51	1.13 (0.68 to 1.89)	0.637
Per-protocol analysis
Placebo^†	67	82	1.00		50	1.00
Anti-Hp+celecoxib^‡	47	84	1.48 (0.91 to 2.40)	0.117	30	0.83 (0.45 to 1.51)	0.537
Anti-Hp+placebo^‡	36	96	2.19 (1.32 to 3.64)	0.002	30	1.08 (0.58 to 2.02)	0.805
Celecoxib+placebo^†	49	102	1.72 (1.07 to 2.76)	0.026	42	1.14 (0.65 to 2.00)	0.658

↵* ORs and 95% CIs were calculated by logistic regression and adjusted for age, sex, smoking and drinking status.
↵† The participants who remained H pylori positive.
↵‡ The participants in whom H pylori was eradicated (negative by carbon-13 urea breath test after 45 days).
Anti-Hp, anti-H pylori treatment.